|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
GLYCOMIMETICS INC (Name of Issuer) |
Ordinary Shares, par value $0.001 per share (Title of Class of Securities) |
38000Q201 (CUSIP Number) |
Robert Atchinson Adage Capital Partners GP, L.L.C., 200 Clarendon Street, 52nd Floor Boston, MA, 02116 617-867-2800 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
06/20/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 38000Q201 |
| 1 |
Name of reporting person
Adage Capital Management, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
50,912.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.37 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IA, PN |
SCHEDULE 13D
|
| CUSIP No. | 38000Q201 |
| 1 |
Name of reporting person
Robert Atchinson | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
50,912.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.37 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN, HC |
SCHEDULE 13D
|
| CUSIP No. | 38000Q201 |
| 1 |
Name of reporting person
Phillip Gross | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
50,912.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.37 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN, HC |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Ordinary Shares, par value $0.001 per share | |
| (b) | Name of Issuer:
GLYCOMIMETICS INC | |
| (c) | Address of Issuer's Principal Executive Offices:
9708 MEDICAL CENTER DRIVE, ROCKVILLE,
MARYLAND
, 20850. | |
Item 1 Comment:
Comments (Optional): This Amendment No. 1 ("Amendment No. 1") amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on November 4, 2024 (the "Schedule 13D"), with respect to the ordinary shares, $0.001 par value per share (the "Ordinary Shares"), of Crescent Biopharma, Inc. (formerly known as GlycoMimetics, Inc.), a Cayman Islands exempted company (the "Issuer"). This Amendment No. 1 amends and restates Item 5 as set forth below and is being filed solely due to changes in the outstanding Ordinary Shares of the Issuer pursuant to the closing of the merger, and related transactions, on June 13, 2025 as contemplated by the Merger Agreement (the "Merger"), as described in the Current Report on Form 8-K filed by the Issuer with the SEC on June 18, 2025, as a result of which the Reporting Persons no longer beneficially own more than 5% of the Ordinary Shares. This Amendment No. 1 is the final amendment to the Schedule 13D, which the Reporting Persons are filing voluntarily to exit the reporting system. Capitalized terms used herein and not otherwise defined in this Amendment No. 1 have the meanings set forth in the Schedule 13D. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each of the Reporting Persons. The percentages used in this Schedule 13D are calculated based upon 13,892,562 Ordinary Shares outstanding as of June 13, 2025 after giving effect to a 1-for-100 reverse stock split that was effected on June 13, 2025, the Merger and a redomestication that was effected on June 16, 2025, as disclosed in the Issuer's Current Report on Form 8-K, filed with the SEC on June 18, 2025. | |
| (b) | See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
The number of Ordinary Shares in this Schedule 13D give effect to the reverse stock split of 1-for-100 effected on June 13, 2025. | |
| (c) | The Reporting Persons did not enter into any transactions in the Ordinary Shares during the past sixty days. | |
| (d) | ACP has the right to receive, and the power to direct the receipt of dividends from, and the proceeds from the sale of, the Ordinary Shares. | |
| (e) | June 13, 2025. | |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|